Mink Therapeutics, INC. 8-K Filing
Ticker: INKT · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1840229
Sentiment: neutral
Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-12-08 16:10:24
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT The Nasdaq Stock Mar
Filing Documents
- inkt-20251114.htm (8-K) — 44KB
- inkt-ex99_1.htm (EX-99.1) — 37KB
- inkt-ex99_2.htm (EX-99.2) — 99KB
- img1737559_0.jpg (GRAPHIC) — 138KB
- 0001193125-25-311229.txt ( ) — 503KB
- inkt-20251114.xsd (EX-101.SCH) — 25KB
- inkt-20251114_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 14, 2025, MiNK Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025. The Company inadvertently did not timely file a Current Report on Form 8-K for such press release. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company also hosted a live conference call on November 14, 2025 at 8:30 AM EST to discuss its financial and operating results for the period. A transcript of the conference call is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. There are no revisions to the results that were presented in the foregoing press release and conference call. The information set forth under Item 2.02 and in Exhibits 99.1 and 99.2 attached hereto is in each case intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit The following exhibits are furnished herewith: 99.1 Press Release dated November 14, 2025 99.2 Transcript of Conference Call dated November 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 8, 2025 By: /s/ Christine M. Klaskin Christine M. Klaskin, Treasurer